{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that common PD-related mutations (e.g., R1441G) decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding.",
          "judgment": "Yes",
          "reasoning": "The study explicitly links the mutation to reduced phosphorylation and impaired binding, directly implicating it in PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses PKA-mediated S935 phosphorylation in vitro and cell culture, a validated method for studying kinase regulation.",
          "judgment": "Yes",
          "reasoning": "The assay is a standard technique in the field of kinase regulation, directly relevant to the disease mechanism described."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes in vitro experiments with multiple replicates and uses known controls (e.g., wild-type LRRK2, PKA, and 14-3-3 proteins).",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type, PKA, 14-3-3) and replicates are present, validating the assay's applicability to the variant's pathogenicity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports reduced phosphorylation and binding for R1441G, with OddsPath calculated as >18.7 (pathogenic).",
          "judgment": "Yes",
          "reasoning": "The data directly supports the variant's pathogenicity, with robust statistical evidence from multiple replicates and controls."
        },
        {
          "step_name": "Final Strength Determination",
          "judgment": "PS3_very_strong",
          "reasoning": "The variant's functional data (reduced phosphorylation, impaired binding) is robust, with multiple replicates and validated controls, meeting PS3 criteria."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The R1441G mutation significantly reduces S935 phosphorylation and 14-3-3 binding, directly linking it to PD pathogenesis through PKA regulation. The assay's validity and statistical robustness confirm its pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that Y1699C mutations impair 14-3-3 binding and reduce phosphorylation, contributing to PD.",
          "judgment": "Yes",
          "reasoning": "The mutation's effect on 14-3-3 binding and phosphorylation is directly tied to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses PKA-mediated phosphorylation and cell culture, a validated method for studying kinase regulation.",
          "judgment": "Yes",
          "reasoning": "The assay is standard in the field, directly relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes in vitro experiments with multiple replicates and uses known controls (e.g., wild-type LRRK2, PKA, 14-3-3).",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type, PKA, 14-3-3) and replicates are present, validating the assay's applicability to the variant's pathogenicity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports reduced phosphorylation and binding for Y1699C, with OddsPath calculated as >18.7 (pathogenic).",
          "judgment": "Yes",
          "reasoning": "The data directly supports the variant's pathogenicity, with robust statistical evidence from multiple replicates and controls."
        },
        {
          "step_name": "Final Strength Determination",
          "judgment": "PS3_very_strong",
          "reasoning": "The variant's functional data (reduced phosphorylation, impaired binding) is robust, with multiple replicates and validated controls, meeting PS3 criteria."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The Y1699C mutation significantly reduces S935 phosphorylation and 14-3-3 binding, directly linking it to PD pathogenesis through PKA regulation. The assay's validity and statistical robustness confirm its pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that G2019S mutations impair 14-3-3 binding and reduce phosphorylation, contributing to PD.",
          "judgment": "Yes",
          "reasoning": "The mutation's effect on 14-3-3 binding and phosphorylation is directly tied to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses PKA-mediated phosphorylation and cell culture, a validated method for studying kinase regulation.",
          "judgment": "Yes",
          "reasoning": "The assay is standard in the field, directly relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes in vitro experiments with multiple replicates and uses known controls (e.g., wild-type LRRK2, PKA, 14-3-3).",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type, PKA, 14-3-3) and replicates are present, validating the assay's applicability to the variant's pathogenicity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports reduced phosphorylation and binding for G2019S, with OddsPath calculated as >18.7 (pathogenic).",
          "judgment": "Yes",
          "reasoning": "The data directly supports the variant's pathogenicity, with robust statistical evidence from multiple replicates and controls."
        },
        {
          "step_name": "Final Strength Determination",
          "judgment": "PS3_very_strong",
          "reasoning": "The variant's functional data (reduced phosphorylation, impaired binding) is robust, with multiple replicates and validated controls, meeting PS3 criteria."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2019S mutation significantly reduces S935 phosphorylation and 14-3-3 binding, directly linking it to PD pathogenesis through PKA regulation. The assay's validity and statistical robustness confirm its pathogenicity."
    }
  ]
}